Coya Therapeutics’ investigational ALS therapy COYA 302 has been granted FDA Fast Track designation while the randomized, double‑blind ALSTARS Phase 2 trial proceeds; the designation speeds agency interaction but does not mean the drug is proven effective. Topline results are expected in early 2027 and will be the decisive checkpoint for safety and potential efficacy.
How COYA 302 is intended to work in ALS
COYA 302 combines low‑dose interleukin‑2 (LD IL‑2) with CTLA‑4 Ig and is given subcutaneously to boost regulatory T cell (Treg) activity while tamping down pro‑inflammatory signals. The objective is not to directly rescue motor neurons but to restore an immune balance that preclinical and early clinical research suggests can slow neuroinflammation, a contributor to ALS progression.
Coya is pursuing multiple Treg‑focused approaches—COYA 302 sits alongside Treg‑derived exosomes and autologous Treg cell programs—so the Phase 2 data will also inform whether a combined immunomodulatory strategy is the most practical next step for their pipeline and partners.
Regulatory milestones, timing and the limits of Fast Track
Fast Track designation gives Coya more frequent FDA meetings, rolling review of submission materials, and potential eligibility for Accelerated Approval or Priority Review if later data meet statutory criteria. That administrative support can shorten review timelines but does not substitute for positive randomized data; Fast Track is a procedural advantage, not evidence of clinical benefit.
Coya’s IND for COYA 302 suffered a nearly one‑month delay because of FDA resource constraints but was ultimately cleared in August 2025—an event that triggered a $4.2 million milestone payment from commercialization partner Dr. Reddy’s Laboratories. The company reported a $7.2 million net loss for Q1 2026 but holds over $50 million in cash and equivalents, including about $11 million raised in a private placement led by Dr. Reddy’s and Greenlight Capital to fund the ALS program and related research.
ALSTARS trial changes, endpoints and the 2027 checkpoint
The ALSTARS Phase 2 study is randomized, double‑blind and placebo‑controlled and uses the ALS Functional Rating Scale‑Revised (ALSFRS‑R) as its primary endpoint; historically, untreated ALS populations decline roughly one point per month on that scale, which provides a comparator for detecting slowing of functional loss. To accelerate enrollment, the protocol was revised to drop exclusions for antihypertensive use and to allow certain controlled autoimmune conditions, which should broaden generalizability but may increase the heterogeneity of immune responses observed.
| Checkpoint | Timing | What it would imply |
|---|---|---|
| Interim safety signals (immune‑related AEs) | Ongoing during enrollment | Serious unexpected events could pause or amend the trial; close monitoring is required given the immunomodulatory mechanism. |
| Topline ALSFRS‑R result | Early 2027 | A statistically and clinically meaningful slowing of decline would support a Phase 3 plan and strengthen any Fast Track/accelerated approval conversations; a null result would likely stop near‑term clinical advancement. |
| Regulatory interaction / rolling review milestones | Post‑Phase 2 if data are positive | Positive data could be submitted on a rolling basis; Fast Track may shorten review but only after convincing efficacy and safety are demonstrated. |
Who should be cautious and what to watch next
Patients and clinicians should view COYA 302 as investigational: Fast Track makes regulatory engagement more frequent but does not change the need for clear randomized evidence. Investors and trial sites should track enrollment speed (affected by broadened criteria), safety reports for immune‑related adverse events, and the prespecified statistical thresholds that will determine whether Phase 2 supports a larger trial.
Quick questions
Does Fast Track mean COYA 302 will be approved? No — Fast Track streamlines development and review but does not indicate clinical efficacy or imminent approval.
When will we know if it works? Topline Phase 2 results from ALSTARS are expected in early 2027; that readout is the main near‑term decision point.
Who holds commercialization rights and who helped fund the program? Dr. Reddy’s Laboratories holds commercialization rights in multiple territories and paid a $4.2 million milestone when the IND cleared in August 2025; Coya also raised about $11 million in a private placement led by Dr. Reddy’s and Greenlight Capital to support the program.